<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Melanin-concentrating hormone (MCH) is an evolutionary conserved hypothalamic neuropeptide that in mammals primarily regulates appetite and energy balance </plain></SENT>
<SENT sid="1" pm="."><plain>We have recently identified a novel role for MCH in <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> by demonstrating attenuated experimental <z:hpo ids='HP_0002583'>colitis</z:hpo> in MCH deficient mice or <z:mp ids='MP_0002169'>wild type</z:mp> mice treated with an anti-MCH antibody </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, targeting MCH has been proposed for the treatment of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Given the link between <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, in the present study we sought to investigate whether blocking MCH might have effects on intestinal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> that are independent of <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODOLOGY: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> development was evaluated in MCH-deficient mice crossed to the APCmin mice which develop spontaneously intestinal <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>A different cohort of MCH-/- and MCH+/+ mice in the APCmin background was treated with <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="9" ids="32149">sodium sulphate</z:chebi> (DSS) to induce <z:mp ids='MP_0001845'>inflammation</z:mp>-dependent <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In Caco2 human colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells, the role of MCH on cell survival, proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was investigated </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: APCmin mice lacking MCH developed fewer, smaller and less dysplastic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in the intestine and colon which at the molecular level are characterized by attenuated activation of the wnt/beta-catenin signaling pathway and increased apoptotic indices </plain></SENT>
<SENT sid="8" pm="."><plain>Form a mechanistic point of view, MCH increased the survival of <z:mp ids='MP_0009314'>colonic adenocarcinoma</z:mp> Caco2 cells via inhibiting <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, consistent with the mouse studies </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: In addition to modulating <z:mp ids='MP_0001845'>inflammation</z:mp>, MCH was found to promote intestinal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> at least in part by inhibiting epithelial cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Thereby, blocking MCH as a therapeutic approach is expected to decrease the risk for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>